The trials demonstrated consistent efficacy of elinzanetant across different BMI and smoking history subgroups, highlighting its broad applicability. Elinzanetant showed greater numerical ...

BMI announced today that Benson Boone will be honored with the BMI champion award at the 2025 BMI Pop Awards on May 13 at Beverly Wilshire in Beverly Hills, Calif. The performing rights ...

Findings showed patients on setmelanotide saw a mean BMI reduction of 16.5% from baseline compared with a 3.3% increase for those on placebo at week 52. Topline data were announced from a phase 3 ...

BMI said this move signals a shift to a more accommodative stance amid manageable inflation and growing downside risks to the country’s economic outlook. “We maintain our forecast that the BSP ...

By Paul Grein Atticus Ross will receive the BMI Icon Award at the 41st annual BMI Film, TV and Visual Media Awards on May 14 in Beverly Hills, Calif. The ceremony will also salute the composers of ...

80% of patients on setmelanotide saw ≥5% BMI reduction after 52 weeks, versus a 3.3% BMI increase on placebo. Setmelanotide cut BMI by 19.2% in adults and 20.2% in patients under 18 compared to ...

BMI Group, a real-estate investment company specializing in infrastructure redevelopment at scale, has purchased a minority stake in Destiny Copper. THOROLD — Destiny Copper, a cleantech mineral ...

In this article, we are going to take a look at where Badger Meter, Inc. (NYSE:BMI) stands against other low profile dividend champions. Companies known as Dividend Aristocrats belong to the S&P ...

THE PHILIPPINES has room to negotiate with the US to lower its reciprocal tariffs, Fitch Solutions’ unit BMI said, but added that trade tensions are still likely to weigh on economic growth. “For now, ...

Participants receiving setmelanotide had a 19.8% greater BMI decrease than those assigned placebo at 1 year. More than half of the setmelanotide group had a BMI reduction of at least 15% during ...

The primary endpoint of mean BMI reduction was -16.5% from baseline for all patients on setmelanotide therapy (n=81) compared with +3.3% BMI change for patients on placebo (n=39) at 52 weeks.